Trials / Completed
CompletedNCT00261092
GEMOX: Oxaliplatin in Pancreatic Cancer
Phase II Multicenter, Open Label Study of Oxaliplatin Combined With Gemcitabine(GEMOX) in Advanced and Metastatic Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (planned)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Primary objective: * To evaluate overall response rate (based on RECIST criterion) Secondary objective: * To evaluate time to progression, clinical benefit, quality of life and safety
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oxaliplatin |
Timeline
- Start date
- 2005-10-01
- First posted
- 2005-12-02
- Last updated
- 2008-04-15
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00261092. Inclusion in this directory is not an endorsement.